questionsmedicales.fr
Maladies de la peau et du tissu conjonctif
Maladies de la peau
Sclérodermie systémique
Sclérodermie diffuse
Sclérodermie diffuse : Questions médicales fréquentes
Diagnostic
5
Sclérodermie
Diagnostic médical
Signes cliniques
Sclérodermie
Radiographie
Sclérodermie
Symptômes
5
Symptômes respiratoires
Sclérodermie
Atteinte digestive
Sclérodermie
Troubles vasculaires
Sclérodermie
Prévention
5
Facteurs de risque
Sclérodermie
Exposition au froid
Sclérodermie
Traitements
5
Corticostéroïdes
Sclérodermie
Kinésithérapie
Sclérodermie
Traitements expérimentaux
Sclérodermie
Symptômes cutanés
Sclérodermie
Complications
5
Complications
Sclérodermie
Atteintes cardiaques
Sclérodermie
Atteintes rénales
Sclérodermie
Complications digestives
Sclérodermie
Facteurs de risque
5
Facteurs de risque
Sclérodermie
Facteurs environnementaux
Sclérodermie
Maladies auto-immunes
Sclérodermie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sclérodermie diffuse : Questions médicales les plus fréquentes",
"headline": "Sclérodermie diffuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sclérodermie diffuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-29",
"dateModified": "2025-02-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sclérodermie systémique",
"url": "https://questionsmedicales.fr/mesh/D012595",
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie systémique",
"code": {
"@type": "MedicalCode",
"code": "D012595",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C17.800.784"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse",
"alternateName": "Scleroderma, Diffuse",
"code": {
"@type": "MedicalCode",
"code": "D045743",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Dinesh Khanna",
"url": "https://questionsmedicales.fr/author/Dinesh%20Khanna",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA."
}
},
{
"@type": "Person",
"name": "Christopher P Denton",
"url": "https://questionsmedicales.fr/author/Christopher%20P%20Denton",
"affiliation": {
"@type": "Organization",
"name": "UCL Division of Medicine, Royal Free Campus, London, UK."
}
},
{
"@type": "Person",
"name": "Ami A Shah",
"url": "https://questionsmedicales.fr/author/Ami%20A%20Shah",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu."
}
},
{
"@type": "Person",
"name": "Susanna Proudman",
"url": "https://questionsmedicales.fr/author/Susanna%20Proudman",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Paclitaxel-induced diffuse scleroderma with possible scleroderma-renal crisis: a case report and literature review of taxanes-induced scleroderma.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36085204",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10067-022-06364-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma Patients.",
"datePublished": "2023-02-01",
"url": "https://questionsmedicales.fr/article/36281773",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42380"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Case of Diffuse Scleroderma Presenting as Hypertensive Encephalopathy Due to Scleroderma Renal Crisis.",
"datePublished": "2024-06-05",
"url": "https://questionsmedicales.fr/article/38975413",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.61732"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interleukin-36α is elevated in diffuse systemic sclerosis and may potentiate fibrosis.",
"datePublished": "2022-06-03",
"url": "https://questionsmedicales.fr/article/35667282",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cyto.2022.155921"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis.",
"datePublished": "2024-07-17",
"url": "https://questionsmedicales.fr/article/39056787",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells13141205"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de la peau et du tissu conjonctif",
"item": "https://questionsmedicales.fr/mesh/D017437"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de la peau",
"item": "https://questionsmedicales.fr/mesh/D012871"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sclérodermie systémique",
"item": "https://questionsmedicales.fr/mesh/D012595"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sclérodermie diffuse",
"item": "https://questionsmedicales.fr/mesh/D045743"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sclérodermie diffuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sclérodermie diffuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sclérodermie diffuse",
"description": "Comment diagnostiquer la sclérodermie diffuse ?\nQuels tests sanguins sont utilisés ?\nLes biopsies cutanées sont-elles nécessaires ?\nQuels signes cliniques sont observés ?\nLa radiographie est-elle utile dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D045743#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sclérodermie diffuse",
"description": "Quels sont les symptômes principaux ?\nLa fatigue est-elle un symptôme courant ?\nY a-t-il des symptômes respiratoires ?\nComment se manifeste l'atteinte digestive ?\nLes troubles vasculaires sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D045743#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sclérodermie diffuse",
"description": "Peut-on prévenir la sclérodermie diffuse ?\nQuels facteurs de risque sont identifiés ?\nLe tabagisme influence-t-il la maladie ?\nL'exposition au froid est-elle un risque ?\nLes infections peuvent-elles aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sclérodermie diffuse",
"description": "Quels traitements sont disponibles ?\nLes corticostéroïdes sont-ils efficaces ?\nQuelles thérapies physiques sont recommandées ?\nY a-t-il des traitements expérimentaux ?\nComment gérer les symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D045743#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sclérodermie diffuse",
"description": "Quelles sont les complications possibles ?\nLa sclérodermie peut-elle affecter le cœur ?\nY a-t-il un risque d'infections ?\nComment la sclérodermie affecte-t-elle les reins ?\nLes complications digestives sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D045743#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sclérodermie diffuse",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils significatifs ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nLe stress peut-il aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la sclérodermie diffuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, les antécédents médicaux et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps spécifiques comme les anticorps anti-Scl-70."
}
},
{
"@type": "Question",
"name": "Les biopsies cutanées sont-elles nécessaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être réalisées pour évaluer l'atteinte tissulaire et confirmer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent un durcissement de la peau, des œdèmes et des troubles vasculaires."
}
},
{
"@type": "Question",
"name": "La radiographie est-elle utile dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aider à évaluer les atteintes pulmonaires ou digestives associées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent un durcissement de la peau, des douleurs articulaires et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue est fréquente et peut être liée à l'inflammation et à l'atteinte organique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des difficultés respiratoires peuvent survenir en raison de l'atteinte pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'atteinte digestive ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se traduire par des reflux, des troubles de la déglutition et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Les troubles vasculaires sont-ils fréquents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des phénomènes de Raynaud et des ulcères digitaux peuvent se produire."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la sclérodermie diffuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention connue, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont identifiés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des expositions environnementales et le sexe féminin."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la maladie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut aggraver les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "L'exposition au froid est-elle un risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition au froid peut déclencher des symptômes vasculaires comme le phénomène de Raynaud."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la maladie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent exacerber les symptômes et compliquer la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs, des anti-inflammatoires et des thérapies symptomatiques."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire l'inflammation, mais leur utilisation doit être prudente en raison des effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles thérapies physiques sont recommandées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La kinésithérapie peut aider à maintenir la mobilité et à réduire la douleur articulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les inhibiteurs de la tyrosine kinase sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes cutanés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crèmes hydratantes et des traitements topiques peuvent aider à soulager les symptômes cutanés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des atteintes pulmonaires, cardiaques et rénales, ainsi que des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La sclérodermie peut-elle affecter le cœur ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des arythmies, une hypertension pulmonaire et une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'infections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être plus susceptibles aux infections en raison d'une immunité altérée."
}
},
{
"@type": "Question",
"name": "Comment la sclérodermie affecte-t-elle les reins ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une hypertension rénale et une insuffisance rénale, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Les complications digestives sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des reflux, des troubles de la motilité et des malabsorption."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le sexe féminin et certaines expositions environnementales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sclérodermie diffuse survient généralement entre 30 et 50 ans, mais peut toucher d'autres âges."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils significatifs ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des solvants organiques et à la silice peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant d'autres maladies auto-immunes peuvent avoir un risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver la maladie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut exacerber les symptômes, bien que son rôle exact dans la sclérodermie ne soit pas clair."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/02/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
4 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Publications dans "Sclérodermie diffuse" :
4 publications dans cette catégorie
Affiliations :
UCL Division of Medicine, Royal Free Campus, London, UK.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy. francescozulian58@gmail.com.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Georgetown University Medical Center, Washington (DC), USA.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Lady Davis Institute of the Jewish General Hospital, 4333 Côte-Sainte-Catherine Road,, Montréal, Québec, H3T 1E4, Canada. brett.thombs@mcgill.ca.
Department of Psychology, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Psychiatry, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Medicine, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Educational and Counselling Psychology, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Biomedical Ethics Unit, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
University of Pittsburgh, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Rheumatology, Justus-Liebig University Giessen, Giessen, Germany.
Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Rheumatology Unit, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy.
Publications dans "Sclérodermie diffuse" :
Scleroderma is a rare complication in taxanes therapy. Although individual cases of taxanes-induced scleroderma have been reported, the clinical manifestation and treatment outcomes were reviewed and ...
A PubMed literature review on published cases of taxanes-induced scleroderma up until April 2022 was included for analysis....
The search identified 27 patients with adequate information for analysis. Of the 28 patients, including the one presented here, 22 were female. Peripheral edema was the most common symptom in all but ...
Taxanes-induced scleroderma is different from idiopathic scleroderma. Physicians should be aware of this condition in order to provide early diagnosis and apply appropriate management in order to avoi...
Patients with diffuse cutaneous systemic sclerosis (dcSSc) display a complex clinical phenotype. Transcriptional profiling of whole blood or tissue from patients are affected by changes in cellular co...
SSc patients were recruited from the Prospective Registry for Early Systemic Sclerosis. Clinical data were collected, as well as peripheral blood for isolation of CMs and NCMs. Age-, sex-, and race-ma...
We used an unbiased approach to cluster patients into 3 groups (groups A-C) based on the transcriptional signatures of CMs relative to controls. Each group maintained their characteristic transcriptio...
We are the first to show that transcriptional signatures of CMs and NCMs can be used to unbiasedly stratify SSc patients and correlate with disease activity outcome measures....
This case report details a rare presentation of diffuse scleroderma, where a 38-year-old female developed hypertensive encephalopathy due to scleroderma renal crisis (SRC). SRC, characterized by sudde...
Systemic sclerosis (SSc) is an autoimmune prototypical connective tissues disease that results in alterations in vasculature, inflammation and fibrosis of the skin. Interleukin-1 family cytokines has ...
Systemic sclerosis (SSc) is an autoimmune connective tissue disease with a triad of features that include vascular abnormalities, inflammation and skin and lung fibrosis. At the core of the disease is...
Diffuse cutaneous systemic sclerosis (SSc) is a highly heterogeneous disease. A provisionally approved Composite Response Index in diffuse cutaneous SSc (CRISS) was developed as a 1-year outcome measu...
Patient profiles from a large observational cohort were created for 50 random diffuse cutaneous SSc patients of <5 years disease duration with improved CRISS scores after 1 year and 50 with non-improv...
Patients had mean ± SD disease duration of 2.2 ± 1.3 years. There was substantial agreement between the physician majority opinion about each case and the CRISS (κ = 0.76 [95% confidence interval (95%...
There was substantial agreement between the dichotomous CRISS rating and physician assessment of diffuse cutaneous SSc patients after 1 year. This supports the use of a CRISS cutoff at 0.6 for improve...
Systemic sclerosis, an autoimmune disease characterized by fibrosis and vasculopathy of the skin and other multiple organs has been associated with an increased risk of malignancy. We present the case...
To evaluate the baseline clinical characteristics of juvenile systemic sclerosis (SSc) patients in the international juvenile SSc inception cohort, and to compare these characteristics between the cla...
A cross-sectional study was performed using baseline visit data. Information on demographic characteristics, organ system evaluation, treatment, and patient- and physician-reported outcomes was extrac...
At data extraction, 150 juvenile SSc patients were enrolled across 42 centers; 83% were White, 80% were female, juvenile dcSSc predominated (72%), and 17% of the cohort had overlap features. Significa...
Results from a large international juvenile SSc cohort demonstrate significant differences between juvenile dcSSc and juvenile lcSSc patients, including more globally severe disease and increased freq...
Scleroderma or systemic sclerosis (SSc) is an autoimmune disease affecting the connective tissue, characterized by fibrosis of the skin and internal organs. There is currently no curative treatment av...
Scleroderma is a complex autoimmune disorder that primarily affects the connective tissue. Its key pathogenesis comprises vascular abnormalities, autoimmunity, and tissue fibrosis. While the exact eti...